Inhibition of brain tumor growth by intravenous poly( -L-malic acid) nanobioconjugate with pH-dependent drug release

Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Proceedings of the National Academy of Sciences (Impact Factor: 9.67). 10/2010; 107(42):18143-8. DOI: 10.1073/pnas.1003919107
Source: PubMed

ABSTRACT Effective treatment of brain neurological disorders such as Alzheimer's disease, multiple sclerosis, or tumors should be possible with drug delivery through blood-brain barrier (BBB) or blood-brain tumor barrier (BTB) and targeting specific types of brain cells with drug release into the cell cytoplasm. A polymeric nanobioconjugate drug based on biodegradable, nontoxic, and nonimmunogenic polymalic acid as a universal delivery nanoplatform was used for design and synthesis of nanomedicine drug for i.v. treatment of brain tumors. The polymeric drug passes through the BTB and tumor cell membrane using tandem monoclonal antibodies targeting the BTB and tumor cells. The next step for polymeric drug action was inhibition of tumor angiogenesis by specifically blocking the synthesis of a tumor neovascular trimer protein, laminin-411, by attached antisense oligonucleotides (AONs). The AONs were released into the target cell cytoplasm via pH-activated trileucine, an endosomal escape moiety. Drug delivery to the brain tumor and the release mechanism were both studied for this nanobiopolymer. Introduction of a trileucine endosome escape unit resulted in significantly increased AON delivery to tumor cells, inhibition of laminin-411 synthesis in vitro and in vivo, specific accumulation in brain tumors, and suppression of intracranial glioma growth compared with pH-independent leucine ester. The availability of a systemically active polymeric drug delivery system that passes through the BTB, targets tumor cells, and inhibits glioma growth gives hope for a successful strategy of glioma treatment. This delivery system with drug release into the brain-specific cell type could be useful for treatment of various brain pathologies.

Download full-text


Available from: Eggehard Holler, Sep 26, 2015
1 Follower
27 Reads
  • Source
    • "The primary barrier to using morpholinos for treatment is achieving adequate levels of modified oligonucleotides in the brain. Several strategies for getting oligonucleotides to cross the blood brain barrier have been described,39,40,41 though these approaches have not yet been tried in man. Other approaches include infusion of oligonucleotides into the cerebrospinal fluid42 or by use of implanted pumps.43 "
    [Show abstract] [Hide abstract]
    ABSTRACT: In Alzheimer's disease, progressive supranuclear palsy, and a number of other neurodegenerative diseases, the microtubule associated protein tau aggregates to form intracellular neurofibrillary tangles and glial tangles, abnormal structures that are part of disease pathogenesis. Disorders with aggregated tau are called tauopathies. Presently, there are no disease-modifying treatments for this disease class. Tau is encoded by the MAPT gene. We propose that reducing MAPT expression and thus the amount of tau protein made could prevent aggregation, and potentially be an approach to treat tauopathies. We tested 31 morpholinos, complementary to the sense strand of the MAPT gene to identify oligonucleotides that can downregulate MAPT expression and reduce the amount of tau protein produced. Oligonucleotides were tested in human neuroblastoma cell lines SH-SY5Y and IMR32. We identified several morpholinos that reduced MAPT mRNA expression up to 50% and tau protein levels up to ~80%. The two most potent oligonucleotides spanned the 3' boundary of exons 1 and 5, masking the 5'-splice sites of these exons. Both morpholinos induced skipping of the targeted exons. These in vitro findings were confirmed in mice transgenic for the entire human MAPT gene and that express human tau protein. These studies demonstrate the feasibility of using modified oligonucleotides to alter tau expression.
    Molecular Therapy - Nucleic Acids 07/2014; 3(7):e180. DOI:10.1038/mtna.2014.30 · 4.51 Impact Factor
  • Source
    • "We postulated that introduction of a CPP (Regberg et al. 2013) into the Cas9 protein might enable its direct delivery into cells. However , when we genetically fused Cas9 to a CPP that consists of four Gly, nine Arg, and four Leu (Matsui et al. 2003; Ding et al. 2010), it was difficult to obtain purified protein in suitable quantities, which is in line with results with ZFNs (Gaj et al. 2012) and TALENs (Liu et al. 2014) fused with several CPPs. Thus, we sought to minimize genetic modification of Cas9 by adding a Cys residue at the C terminus (Fig. 1) to enable CPP conjugation after Cas9 expression. "
    [Show abstract] [Hide abstract]
    ABSTRACT: RNA-guided endonucleases (RGENs) derived from the CRISPR/Cas system represent an efficient tool for genome editing. RGENs consist of two components: Cas9 protein and guide RNA. Plasmid-mediated delivery of these components into cells can result in uncontrolled integration of the plasmid sequence into the host genome and unwanted immune responses and potential safety problems that can be caused by the bacterial sequences, and requires transfection tools for mediating the delivery. Here we show that simple treatment with cell-penetrating peptide (CPP)-conjugated recombinant Cas9 protein and CPP-complexed guide RNAs lead to endogenous gene disruptions in human cell lines. The Cas9 protein was conjugated to CPP via a thioether bond, whereas the guide RNA was complexed with CPP, forming condensed, positively charged nanoparticles. Simultaneous and sequential treatment of human cells, including embryonic stem cells, dermal fibroblasts, HEK293T cells, HeLa cells, and embryonic carcinoma cells, with the modified Cas9 and guide RNA leads to efficient gene disruptions with reduced off-target mutations relative to plasmid transfections, resulting in the generation of clones containing RGEN-induced mutations. Our CPP-mediated RGEN delivery process provides a plasmid-free and additional transfection reagent-free way to use this tool with reduced off-target effects. We envision that our method will facilitate RGEN-directed genome editing.
    Genome Research 04/2014; 24(6). DOI:10.1101/gr.171264.113 · 14.63 Impact Factor
  • Source
    • "We have demonstrated the successful delivery of several anti cancer agents specifically to brain and breast tumor using the targeted nanoconjugate delivery system Polycefin including temozolomide [26] and antisense oligonucleotides [27–29]. This system uses the nanoscale platform poly(β-l-malic acid) (PMLA) known to be biodegradable, non-toxic and non-immunogenic. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Doxorubicin (DOX) is currently used in cancer chemotherapy to treat many tumors and shows improved delivery, reduced toxicity and higher treatment efficacy when being part of nanoscale delivery systems. However, a major drawback remains its toxicity to healthy tissue and the development of multi-drug resistance during prolonged treatment. This is why in our work we aimed to improve DOX delivery and reduce the toxicity by chemical conjugation with a new nanoplatform based on polymalic acid. For delivery into recipient cancer cells, DOX was conjugated via pH-sensitive hydrazone linkage along with polyethylene glycol (PEG) to a biodegradable, non-toxic and non-immunogenic nanoconjugate platform: poly(β-l-malic acid) (PMLA). DOX-nanoconjugates were found stable under physiological conditions and shown to successfully inhibit in vitro cancer cell growth of several invasive breast carcinoma cell lines such as MDA-MB-231 and MDA-MB- 468 and of primary glioma cell lines such as U87MG and U251.
    International Journal of Molecular Sciences 12/2012; 13(9):11681-93. DOI:10.3390/ijms130911681 · 2.86 Impact Factor
Show more